Alaunos Therapeutics Reports Material Definitive Agreement & Equity Sales
Ticker: TCRT · Form: 8-K · Filed: Jun 26, 2025 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
TL;DR
Alaunos Therapeutics filed an 8-K detailing a new deal, equity sales, and charter changes.
AI Summary
Alaunos Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting on several key events as of June 24, 2025. These include entering into a material definitive agreement, unregistered sales of equity securities, material modifications to security holder rights, and amendments to its articles of incorporation or bylaws. The company, formerly known as ZIOPHARM ONCOLOGY INC, is based in Houston, Texas.
Why It Matters
This filing indicates significant corporate actions, including potential new financing or strategic partnerships and changes in equity structure, which could impact the company's financial standing and shareholder value.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Alaunos Therapeutics, Inc. (company) — Registrant
- ZIOPHARM ONCOLOGY INC (company) — Former Company Name
- June 24, 2025 (date) — Date of earliest event reported
- June 26, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Houston, TX (location) — Principal business address
FAQ
What is the nature of the material definitive agreement entered into by Alaunos Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one was entered into as of June 24, 2025.
What type of equity securities were sold in the unregistered sale?
The filing states there were unregistered sales of equity securities but does not provide specific details on the type or amount of securities sold.
What are the material modifications to the rights of security holders?
The filing indicates material modifications to the rights of security holders occurred, but the specific nature of these modifications is not detailed in the provided text.
What amendments were made to Alaunos Therapeutics' articles of incorporation or bylaws?
The filing lists amendments to articles of incorporation or bylaws as an item reported, but the specific changes are not described in this excerpt.
When was Alaunos Therapeutics formerly known as ZIOPHARM ONCOLOGY INC?
The company's name was changed from ZIOPHARM ONCOLOGY INC on September 19, 2005.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 26, 2025 regarding Alaunos Therapeutics, Inc. (TCRT).